Shingles vaccine candidate shows high efficacy in adults 70 and older
by Press Release from Outbreak News Today on (#1TYPS)
GlaxoSmithKline (GSK) announced the publication of detailed results from a randomized phase III study (ZOE-70) of its investigational shingles vaccine, showing 90% efficacy in adults aged 70 years and older that is maintained for at least four years. The results were published in the New England Journal of Medicine (NEJM). The study, from which headline results ["]